Categories
Business Lifestyle

City of Detroit 911 to implement NICE Inform Elite to improve service to citizens and communities

911 communications center for largest city in Michigan aims to improve productivity, staff performance and satisfaction, and elevate 911 service with assistance from NICE technology

 

HOBOKEN, N.J. — (BUSINESS WIRE) — #NICENICE (Nasdaq: NICE) today announced that the City of Detroit (Michigan) 911 communications center will be deploying NICE Inform Elite to digitally transform processes around tracking performance metrics, performing quality assurance reviews, and reconstructing incidents. Through this transformation, the 911 center expects to improve productivity, enhance staff performance and satisfaction and provide better service to citizens and communities. Detroit is the largest city in the state of Michigan and the 27th most populous U.S. city with over 639,000 residents.

NICE Inform Elite features Intelligence Center dashboards with dozens of real-time metrics that offer instant visibility into what’s happening in the 911 center, and why. Metrics can be viewed on an overall 911 center level, or by individual telecommunicator, the agency served (police, fire, EMS) or incident priority or type. The solution automatically consolidates data from various 911 center systems into meaningful metrics which are presented on intuitive dashboards. Managers can drill through metrics to the underlying 911 incident recordings for context.

 

Art Thompson, Chief Information Officer, City of Detroit, said, “With over a million 911 calls received annually, our call volume is on par with the top 10 US cities. Citizens call us during their most vulnerable moments. We want to do everything we can to take 911 to the next level. NICE’s performance metric capabilities are going to help us hold ourselves accountable. We’re also looking to NICE’s solutions to help us better self-reflect and support our front-line telecommunicators, so they can be successful in their careers. We plan to use the dashboards to better understand the types of calls telecommunicators are taking, and their impact, so we can further enhance staff performance and satisfaction and the level of service we provide to citizens.”

 

Chris Wooten, Executive Vice President, NICE, said, “As a single system of record that sits at the center of the 911 data ecosystem, our NICE Inform Elite solution brings all incident-related data together from multiple systems to give 911 centers a single view of the truth and automate incident reconstructions and Quality Assurance. We give 911 managers the operational intelligence and free up the time they need to provide targeted training and coaching to telecommunicators, improve incident response and keep communities safer.”

 

The Detroit 911 center, which currently partners with an outside agency to randomly quality check calls, will also use NICE technology to take a more proactive approach to 911 Quality Assurance (QA). When metrics reveal calls where telecommunicators need additional assistance, managers will be able to assign these calls for QA review directly through the dashboard. Additionally, the center will focus more heavily on reviewing medical calls, thanks to NICE Inform Elite’s ability to use computer-aided dispatch (CAD) incident data to automatically pull specific types of high priority calls for quality assurance review.

 

When a full review of incidents is necessary, NICE Inform Elite can also streamline incident reconstruction. The solution automatically pulls 911, dispatch and first responder radio communications and associated CAD incident data into a timeline view, so managers are able to synchronously replay incidents exactly as they happened.

 

“We run pretty lean for a 911 center,” Thompson added. “Anywhere we can improve processes by having technology assist and cut down on man hours is monumental. With our current technology, we have to go into multiple systems to retrieve recordings and understand what happened. By migrating to NICE, we’ll be able to capture everything in one system for a complete picture, which will significantly cut down on time spent investigating incidents and help us answer questions faster. NICE Inform Elite checks all the boxes for us.”

 

To learn more about NICE Inform Elite:

 

About NICE Public Safety

With over 3,000 customers and 30 years’ experience, NICE delivers end-to-end digital transformation, improved collaboration, efficiency and cost-savings to all types of public safety and criminal justice agencies, from emergency communications centers and police departments to prosecutors and courts. Our Evidencentral platform (which includes NICE Inform, NICE Investigate, NICE Justice and E-Request) features an ecosystem of integrated technologies that bring data together to improve incident response, accelerate investigations, streamline evidence sharing and disclosure, and keep communities and citizens safer.

 

About the Detroit 911 Center

Staffed by 30 highly trained licensed Public Safety Emergency Medical Technicians and Medical First Responders, the Detroit 911 Center operates 24 hours a day, 365 days of the year, serving 639,000 city residents within a 143 square mile area, and responding to over a million police, fire and emergency medical calls from the public annually. Detroit is the largest city in the midwestern state of Michigan and the 27th most populous U.S. state. More info at https://detroitmi.gov/departments/detroit-fire-department/communications

 

About NICE

With NICE (Nasdaq: NICE), it’s never been easier for organizations of all sizes around the globe to create extraordinary customer experiences while meeting key business metrics. Featuring the world’s #1 cloud native customer experience platform, CXone, NICE is a worldwide leader in AI-powered self-service and agent-assisted CX software for the contact center – and beyond. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, partner with NICE to transform – and elevate – every customer interaction. www.nice.com.

 

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

 

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Wooten, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media Contact
Christopher Irwin-Dudek, +1 201 561 4442, ET, chris.irwin-dudek@nice.com

Investors
Marty Cohen, +1 551 256 5354, ET, ir@nice.com
Omri Arens, +972 3 763 0127, CET, ir@nice.com

Categories
Business Technology

PARTS iD, Inc. announces participation in 2022 ICR Conference

CRANBURY, N.J. — (BUSINESS WIRE) — PARTS iD, Inc. (NYSE American: ID) (“PARTS iD” or “Company), the owner and operator of, among other verticals, “CARiD.com,” a leading digital commerce platform for the automotive aftermarket, announced today that Chief Executive Officer, Nino Ciappina, and Chief Financial Officer, Kailas Agrawal are participating in the 2022 ICR Conference.

 

Management is scheduled to present on Monday, January 10, 2022 at 10:30 a.m. Eastern Time. A live webcast of the presentation will be available at https://www.partsidinc.com/.

 

About PARTS iD, Inc.

PARTS iD is a technology-driven, digital commerce company focused on creating custom infrastructure and unique user experiences within niche markets. Founded in 2008 with a vision of creating a one-stop eCommerce destination for the automotive parts and accessories market, management believes that the Company is a market leader and proven brand-builder, fueled by its commitment to delivering a revolutionary shopping experience; comprehensive, accurate and varied product offerings; and continued digital commerce innovation.

Contacts

Investors:
Brendon Frey

ICR

ir@partsidinc.com

Media:
Erin Hadden

FischTank PR

partsid@fischtankpr.com

Categories
Business Science

Cyclenium Pharma and Vuja De Sciences announce oncology drug discovery collaboration

The companies will identify and advance proprietary lead drug candidates uniquely suited to prevent metastatic recurrence.

 

NATICK, Mass. & HOBOKEN, N.J. & MONTREAL — (BUSINESS WIRE) — Cyclenium Pharma, Inc. (“Cyclenium”), an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. (“Vuja De”), a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will screen and optimize lead candidates to advance treatments uniquely suited for preventing cancer metastatic recurrence, the biggest unmet need in oncology.

The collaboration will exploit Vuja De’s proprietary anti-metastatic progression in vitro and ex vivo drug discovery screening platform and Cyclenium’s proprietary QUEST™ Library of next generation synthetic small-molecule macrocycles and associated optimization expertise to identify clinical candidates effective against dormant disseminated tumor cells for the prevention of metastatic cancer recurrence. Vuja De will be responsible for all screening efforts, while Cyclenium will be responsible for all medicinal chemistry efforts to generate new optimized macrocyclic compounds by employing its unique CMRT™ Technology.

 

“We are very excited about entering this collaboration with Vuja De,” stated Helmut Thomas, Ph.D., President, Chief Executive Officer & Chief Scientific Officer of Cyclenium. “We are confident that our CMRT™ Technology and proven success in the macrocycle area combined with the innovative anti-metastatic progression platform and excellent research team at Vuja De will enable the discovery and development of novel macrocyclic therapeutic agents to effectively control metastatic progression.”

 

“We highly appreciate Cyclenium’s expertise in the macrocycle area and their technology platform that is based on over 20 years of pioneering experience in small molecule macrocyclic chemistry,” said David Warshawsky, Ph.D., Chief Executive Officer of Vuja De. “We are very pleased to work with Cyclenium on identifying and developing novel game-changing drug candidates that prevent metastatic recurrence, the most urgent need of most cancer patients,” he added.

 

About Cyclenium Pharma

Cyclenium Pharma is an emerging, privately held pharmaceutical research and development company exploiting its proprietary next generation CMRT™ macrocyclic drug discovery technology for the discovery and development of novel small molecule therapeutic agents to address areas of unsatisfied medical need. Cyclenium is creating value through progression of internal programs in oncology, infectious diseases and inflammation/pain. In addition, Cyclenium is providing its extensive experience and exploring its CMRT-based QUEST™ screening library in risk-sharing partnerships with leading academic and research driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies world-wide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. For more information see: www.cyclenium.com.

 

About Vuja De Sciences

Vuja De is a biotechnology startup company dedicated to discovering and developing therapies that target the unique vulnerability of undetected disseminated tumor cells (DTCs) before they can cause deadly metastatic cancer recurrence. This vulnerability of DTCs stems from their dependence on a unique phenotype that includes stress adaptation, survival & dormancy, which we have coined “Metastatic Endurance” (ME). ME enables DTCs to persist undetected at secondary sites like “ticking time-bombs” and eventually start to rapidly divide and form overt deadly tumors. We successfully created the first-ever cell-based and ex vivo drug screening platform that finds drugs that target ME. We are using the largely adolescent, orphan disease, osteosarcoma, as the best proof of concept model for developing anti metastatic progression drugs for many cancers such as breast, melanoma and kidney. We are testing repurposed drugs that have previously been in clinical trials, as well as novel preclinical drugs. For more information, please visit vujade-life.com.

 

About Osteosarcoma

Osteosarcoma is an aggressive cancer of the bone and is the most common type of bone cancer in children and teens. Since metastatic recurrence has shared biological mechanism in many other cancer types, therapies that show promise in osteosarcoma can be developed in parallel for many other cancer types, such as breast, kidney and melanoma. Despite successful control of the primary osteosarcoma tumors and follow-up chemotherapy, metastasis continues to be the most common cause of mortality. The last 30 years have brought little improvement in survival outcomes for children with osteosarcoma, despite intensification of therapy. Due to lack of improved outcomes, new approaches to therapy are highly needed. Furthermore, if targeted therapeutics are found to prevent metastasis in this cancer, a strong biological rationale would exist for the evaluation of such a therapy in other human cancers.

Contacts

MEDIA:

David Warshawsky, Ph.D.

CEO, Vuja De Sciences

dw@vujade-life.com
+1-857-204-3628

Helmut Thomas, Ph.D.

President, CEO & CSO

Cyclenium Pharma Inc.

hthomas@cyclenium.com
+1-819-571-4296

Categories
Business Lifestyle

Best’s Review examines in-person conference developments and industry innovations for 2022

OLDWICK, N.J. — (BUSINESS WIRE) — The January issue of Best’s Review looks at what worked for in-person events in 2021 and what organizers are doing to prepare for them in 2022 in the following articles:

 

Also included in the January issue:

 

Best’s Review is AM Best’s monthly insurance magazine, covering emerging insurance issues and trends and evaluating their impact on the marketplace. Full access to the complete content of Best’s Review is available Full access to the complete content of Best’s Review is available here.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2022 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Patricia Vowinkel
Executive Editor, Best’s Review®
+1 908 439 2200, ext. 5540

patricia.vowinkel@ambest.com

Categories
Business Healthcare

First ‘Medical Travel Month’ January 2022: Medical Travel & Digital Health News sponsors inclusion in Society for Healthcare Marketing & Development, American Hospital Association’s Calendar of Health Observances & Recognition Days

MAHWAH, N.J. — (BUSINESS WIRE) — Medical Travel & Digital Health News (MTDHN), the leading bi-monthly online newsletter covering the business of medical travel and digital solutions worldwide, today announces its sponsorship of the first “Medical Travel Month” for January 2022, to be included in the Society for Health Care Strategy & Market Development, American Hospital Association’s “ 2022 Calendar of Health Observances & Recognition Days.”

“Medical Travel Month raises awareness for quality medical care options beyond what is available locally,” says Laura Carabello, executive editor and publisher, MTDHN. “Traveling for care, both domestically and internationally, allows Americans to access high-quality, affordable medical care for many treatments and procedures. By raising awareness for medical tourism, we can demonstrate to employers and individuals the value of accessing care from Centers of Excellence or other settings throughout the country.”

In the wake of the COVID-19 pandemic, many Americans have lost insurance coverage as a result of unemployment, encountered higher medical expenses and faced high out-of-pocket expenses under high-deductible plans. These factors fueled an upsurge in domestic and international medical travel as employers have struggled to provide high quality care at lower cost.

Heather Ridenoure, senior director of Product, Contigo Health, which leads partnerships between large national employers and hospital systems, says, “We’ve learned a lot from the coronavirus and saw a decrease in the number of medical travelers during the height of the pandemic. That has changed drastically in the last six months with a significant increase, and we are looking at items, such as virtual evaluations and assessments, with providers prior to traveling. Virtual therapy services are also on the rise to meet the needs of individuals when they return home. We are working hard to make appropriate medical and surgical care accessible for everyone.”

According to Dr. Maan Fares, chairman, Global Patient Services, Cleveland Clinic, “During the beginning of the pandemic, there had been an enormous impact on the ability of patients to travel for healthcare for various reasons. A remarkable exception was the pediatric population which continued to travel despite all difficulties. After the severe decline of patient travel at the height of the pandemic, we have seen a significant demand for international patients seeking care in the United States.”

Patients started to seek care at various stages of the pandemic, with an overall steady increase overtime.

Fares adds, “As a global healthcare organization, we are lucky to have been able to provide healthcare for our patients closer to where they live because of our global footprint of locations, including Toronto, Abu Dhabi, Ohio, Florida and Nevada. This has helped during the pandemic. Also, our distance/digital health teams have been able to connect with our patients to provide care and advice within the comfort of their homes during this time.”

Fare notes that as the vaccine became more available across different markets, they saw a steady increase in patients, concluding, “We are optimistic that with increasing global levels of vaccination, patients will be able to travel for their healthcare needs and won’t have to delay receiving care.”

Hospitals and medical travel facilities are invited to submit a 500-word descriptor with photos to be featured in MTDHN at no charge editor@medicaltraveltoday.com.

About Medical Travel & Digital Health News

MTDHN, a leading international B2B online newsletter, reaches self-insured employers, benefits consultants, TPAs, brokers, stop loss companies and other intermediaries. www.medicaltraveltoday.com

Contacts

Media:
Dylan Matukaitis

CPR Communications

dmatukaitis@cpronline.com
201.641.1911 x 49

Categories
Business Local News

Rocket Pharmaceuticals to present at the 40th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J. — (BUSINESS WIRE) — Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10 at 1:30 p.m. ET.

A live audio webcast of the presentation will be available under “Events” in the Investors section of the Company’s website at https://ir.rocketpharma.com/. The webcast replay will be available on the Rocket website following the conference.

 

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

 

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding its guidance for 2022 in light of COVID-19, the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, Rocket’s plans for the advancement of its Danon Disease program following the lifting of the FDA’s clinical hold and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2020, filed March 1, 2021 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Media

Kevin Giordano

Director, Corporate Communications

kgiordano@rocketpharma.com

Investors

Mayur Kasetty, M.D., M.B.A.

Director, Business Development & Operations

investors@rocketpharma.com

Categories
Business Healthcare

Eagle Pharmaceuticals to present at the 40th Annual J.P. Morgan Healthcare Conference

WOODCLIFF LAKE, N.J. — (BUSINESS WIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference as follows:

Date:

Wednesday, January 12, 2022

Time:

4:30PM ET

Webcast:

https://jpmorgan.metameetings.net/events/healthcare22/sessions/39965-eagle-pharmaceuticals/webcast?gpu_only=true&kiosk=true

 

The webcast of the presentation will be accessible for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors section.

 

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

 

Contacts

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson

In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

Categories
Business Lifestyle

GO, car subscription startup, launches in 4 additional markets

This Brings The Popular Alternative to Car Ownership to Atlanta, Dallas, Houston and Charlotte

PHILADELPHIA — (BUSINESS WIRE) — GO, a first-of-its-kind car subscription startup, announced the addition of 4 new markets today. GO is now available in 8 major U.S. markets. These include Philadelphia, Northern New Jersey, Miami, Orlando, Atlanta, Dallas, Houston, and Charlotte. More markets will be announced mid-year.

 

Distinct from traditional auto lease and finance, GO’s model offers subscribers a simple and affordable alternative to car ownership.

 

“We’ve had tremendous demand for our offering and are pleased to bring GO to customers in these new cities,” said Michael Beauchamp, GO’s Founder and CEO.

 

Through the service, customers in available markets can order their car completely online in under 5 minutes and save up to 25% per month. There’s no down payment and no hidden fees. The entire process is handled virtually without stepping foot in a physical location. In most cases, cars are even delivered to the customer’s home at no charge.

 

GO is the first company to offer a car subscription service geared specifically toward daily drivers, unlike previous car subscriptions that focused on swapping vehicles and short-term use. With significant advantages over the typical car buying process, GO’s innovative model brings evolution to the industry and represents a new paradigm for car shopping.

 

“GO was created to streamline and simplify an antiquated process. Customers win thanks to technology and efficiency driving our unique business model,” said Beauchamp.

 

To learn more about GO, visit https://www.driveGO.com

Contacts

Company Name: GO

Contact Person: Michael Beauchamp

Phone Number: 855-827-2230

Website: www.driveGO.com

Categories
Business News Now!

Alpine Investors sells MidAmerica Administrative & Retirement Solutions to U.S. Retirement & Benefits Partners

SAN FRANCISCO & TAMPA, Fla. — (BUSINESS WIRE) — Alpine Investors (“Alpine”), a people-driven private equity firm, today announced the sale of its portfolio company, MidAmerica Administrative & Retirement Solutions (“MidAmerica”) to U.S. Retirement & Benefits Partners (“USRBP”). MidAmerica administers retirement and health & welfare plans for public sector employers. Terms of the sale were not disclosed.

MidAmerica was founded in 1995 with the goal of making health & retirement benefits funding simple and effective for public school employees, firefighters, law enforcement officers, and other public sector workers across the country.

 

In 2015, Alpine acquired MidAmerica with the aim of developing and empowering its team and bringing awareness to its products. Through its CEO program, Alpine hired and installed MidAmerica’s CEO, Jim Tormey, who built out a strong management team focused on providing valuable benefits funding and administration solutions. Jim Tormey and the MidAmerica management team will continue with the Company in their current roles.

 

MidAmerica has since become a leading third-party administrator providing both retirement and health & welfare solutions for the public sector. Under Tormey’s leadership, client retention soared to over 99% each year and its employee Net Promotor Score increased over 70 points. The team drove substantial improvements in its service offering as demonstrated by a significant decrease in claims processing times, average call wait time, and call abandonment rates.

 

“Jim’s people-driven mindset and customer-centric focus has created both a strong team culture and an ever-growing list of happy customers. We look forward to the next phase of growth for MidAmerica under the support and strategic guidance of USRBP,” said Matt Moore, partner at Alpine.

 

“Over the last few years, the team at MidAmerica has prioritized continuous improvement which has resulted in best-in-class service quality, renewed trust from our customers, and an uptick in organic growth,” said Jim Tormey. “Our partnership with USRBP will allow MidAmerica to continue on its mission of allowing public sector employers to reduce costs, attract and retain great talent, and deliver financial peace of mind for their employees.”

 

Raymond James served as the exclusive financial advisor to MidAmerica and Wilson Sonsini served as legal counsel.

 

About Alpine Investors

Alpine Investors is a people-driven private equity firm that is committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in middle-market companies in the software and services industries. Its PeopleFirst strategy includes a CEO-in-Residence program which allows Alpine to bring proven leadership to situations where additional or new management is needed post-transaction. Alpine is currently investing out of its $1 billion seventh fund. For more information, visit http://www.alpineinvestors.com.

 

About MidAmerica Administrative & Retirement Solutions

Founded in Lakeland, Florida in 1995, MidAmerica was built with a customer-centric culture, laying the foundation for an organization that focuses on taking care of the people who do so much to serve our communities. Currently, MidAmerica services more than half a million participants across 33 states. For more information, visit www.mymidamerica.com.

 

About U.S. Retirement & Benefits Partners

U.S. Retirement & Benefits Partners, with headquarters in Iselin, NJ, is one of the nation’s largest independent, national financial services firms specializing in employee benefit and employer-sponsored retirement plans in the K-12 public school, governmental, corporate, and non-profit markets. USRBP serves over 2.5 million participants through 45 regional Partner Firms. For more information, visit www.usrbpartners.com.

Contacts

Audrey Harris

aharris@alpineinvestors.com

Categories
Business Healthcare Regulations & Security

Teva statement following New York jury ruling in opioids trial

PARSIPPANY, N.J. — (BUSINESS WIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) strongly disagrees with today’s outcome and will prepare for a swift appeal as well as continue to pursue a mistrial.

In NY, the plaintiffs presented no evidence of medically unnecessary prescriptions, suspicious or diverted orders, no evidence of oversupply by the defendants – or any indication of what volumes were appropriate – and no causal relationship between Teva’s conduct including its marketing and any harm to the public in the state.

 

Prior to deliberation, Teva sought a mistrial based on, among other issues, the state’s misrepresentation of the amount of opioids sold by Teva in NY by more than 500 times.

 

Teva continues to focus on increasing access to essential medicines to patients, including opioid medications for approved indications. Most importantly, the Company continues to pursue a national settlement in the best interest of patients.

 

As recently as last month, a court in California issued a decision finding that Teva did not cause a public nuisance in Orange County, Los Angeles County, Santa Clara County and the City of Oakland and that Teva did not make any false or misleading statements in connection with marketing prescription opioids in California.

 

Additionally, last month the Oklahoma Supreme Court overturned an earlier judgment against a pharmaceutical manufacturer and ruled that the public nuisance law in Oklahoma does not extend to the manufacturing, marketing and selling of prescription opioids.

Contacts

IR Contacts

United States
Ran Meir

(267) 468-4475

Israel
Yael Ashman

972 (3) 914-8262

PR Contacts

United States
Kelley Dougherty

(973) 658-0237

Yonatan Beker

(973) 264 7378